Added to YB: 2025-10-28
Pitch date: 2025-10-01
NKTR [bullish]
Nektar Therapeutics
+27.07%
current return
Author Info
No bio for this author
Company Info
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing therapies that selectively modulate the immune system to treat autoimmune disorders in the United States and internationally.
Market Cap
$1.9B
Pitch Price
$58.80
Price Target
125.00 (+67%)
Dividend
N/A
EV/EBITDA
-14.51
P/E
-8.73
EV/Sales
29.18
Sector
Pharmaceuticals
Category
special_situation
Potential Eli Lilly Vehicle for the Acquisition of Nektar Therapeutics (NASDAQ: NKTR)
NKTR: Potential LLY acquisition target. TAHOE ACQUISITION CORP incorporated Oct 15 matching LLY's nature-themed acquisition vehicle pattern. Timing aligns with litigation pause (Oct 14), positive Phase 2b eczema data, & takeover chatter. Peak sales potential $1.5-2B could justify ~$2.5B buyout (~100% premium to $62.50).
Read full article (3 min)